Chief Accounting Officer
Arcutis Biotherapeutics, Inc. (ARQT)Equibles does not estimate personal net worth.
Get an email with a short summary when Arcutis Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ARQT alertsDavid Topper is recorded as Chief Accounting Officer at Arcutis Biotherapeutics, Inc. (ARQT) since April 10, 2024. Arcutis Biotherapeutics, Inc. reported in an 8-K filed April 10, 2025 that David Topper retired as Chief Financial Officer, effective May 15, 2025. Arcutis Biotherapeutics, Inc. reported in an 8-K filed April 10, 2024 that David Topper was appointed principal accounting officer, effective April 10, 2024. Arcutis Biotherapeutics, Inc. reported in an 8-K filed April 10, 2024 that David Topper was appointed Chief Financial Officer, effective April 10, 2024. The proxy statement of Arcutis Biotherapeutics, Inc. reports total compensation of $1,946,733 for David Topper in fiscal 2025, including a base salary of $196,458. Disclosed compensation is on record for 2 fiscal years. David Topper has spoken on 4 earnings calls across 1 company, most recently for Arcutis Biotherapeutics, Inc. on January 13, 2025. Arcutis Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcutis Biotherapeutics, Inc. includes Todd Franklin Watanabe (CEO and Board Member), Latha Vairavan (CFO), Masaru Matsuda (General Counsel) and 7 others.
“Ms. Vairavan will succeed Mr. David Topper, who will transition out of his role as the Company's Chief Financial Officer and retire.”
“Consistent with the foregoing, Mr. Topper will assume the roles of principal financial officer and principal accounting officer of the Company.”
“I'm on slide 21, showing financial results both year-over-year and quarter-over-quarter for the fourth quarter. We generated net product revenues in the quarter of approximately $69.4 million which is up 413% from Q4 of 2023 and 55% from Q3 of this year.”
“I'm on Slide 20, showing financial results, both year-over-year and quarter-over-quarter. As you've heard, we generated net product revenues in the quarter of approximately $45 million, which is up 452% from Q3 of 2023 and 45% from Q2 of this year.”
“I'm on Slide 21 showing financial results both year-over-year and quarter-over-quarter. As you've heard, our net product revenues for the quarter were $30.9 million, which is up 547% from Q2 of '23 and 43% from Q1 of this year.”
“I first want to say how thrilled I am to be at Arcutis and working with this team. It's certainly an exciting quarter to be joining the company. I'm on Slide 21.”
2024-04-10–present
2024-04-10–2025-05-15
Start not stated–2025-05-15
Biotechnology · Healthcare
Chief Accounting Officer
2024-04-10–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Arcutis Biotherapeutics, Inc. (ARQT) | Former Chief Financial Officer | $196,458 | $1,946,733 |
| 2024 | Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | $364,792 | $5,311,203 |
